# C1-A Final Review and Correction Register

**Review date:** 05 August 2026  
**Repository:** `majidhussainqadri1-dot/cf-01-clinical-records-prescription-follow-up`  
**Branch:** `codex/cf-01-c1-a-foundation`  
**Scope:** governance, architecture, evidence integrity, repository policy and merge-readiness only. No clinical runtime or real patient-data authorization is created by this review.

## 1. Review method

The final review used a fresh adversarial pass over the pull-request metadata, all changed files, current GitHub Actions evidence, native-owner tracking issues and the current status of dependent pull requests. Every confirmed defect was corrected in the same cycle and then subjected to a separate regression-oriented review.

The governing distinction remains mandatory:

- merging this governance foundation may record architecture and controls on `main`;
- it does not complete C1-A external acceptance;
- it does not authorize C1-B runtime, patient tables, clinical routes, migration, real attachments or real patient data.

## 2. Confirmed defects corrected

### D-01 — Stale self-referential evidence manifest

The committed evidence manifest named an obsolete branch head, merge ref, workflow run and job. A committed file cannot truthfully certify its own final commit SHA because updating the file changes that SHA.

**Correction:** the manifest now defines a non-self-referential evidence law. Exact immutable head/run/job evidence is recorded by GitHub checks and the final pull-request body after the last content commit; historical values are not represented as current acceptance evidence.

### D-02 — Incomplete required-package validation

The validator did not require the evidence manifest or cross-repository contract-tracking register even though the README declared both part of the C1-A governance package.

**Correction:** both documents, plus this final review register, are mandatory repository surfaces with semantic markers.

### D-03 — Duplicate functional-requirement mappings could pass

The traceability validator converted mapped requirement IDs to a set. A requirement could therefore appear multiple times while still satisfying presence checks.

**Correction:** requirement mappings are counted; every `CF01-FR-001` through `CF01-FR-032` must occur exactly once in the structured phase tables.

### D-04 — Hidden generated/dependency trees could evade inspection

Generated and dependency directories such as `__pycache__`, `node_modules`, `vendor`, virtual environments and build/artifact trees were ignored. A tracked file under one of those paths could therefore avoid policy inspection.

**Correction:** these paths are now prohibited during C1-A rather than silently ignored.

### D-05 — Split sensitive-path variants were not rejected

The previous path check examined each path component separately. A split path such as `clinical/data/...` could evade a `clinicaldata` rule.

**Correction:** the validator now checks both individual normalized components and the normalized full relative path.

### D-06 — Workflow supply-chain and runner drift

The workflow used floating action tags and `ubuntu-latest`, retained checkout credentials by default and did not distinguish exact-head validation from pull-request merge-ref compatibility.

**Correction:** action references are pinned to exact commits, the runner is fixed to `ubuntu-24.04`, checkout credentials are not persisted, exact PR head and merge-ref compatibility are separate jobs, and whitespace integrity is enforced.

### D-07 — Cross-repository status was stale

The tracking register said File 00 PR #13 was unmerged. Current GitHub evidence shows that PR #13 merged on 03 August 2026 as merge commit `ebc66a3782ee846437fe14628dfe7b2a9bc31671`. The provider issue remains open and its acceptance checklist remains incomplete.

**Correction:** the register now distinguishes merged provider code from an accepted/frozen cross-file contract. File 00 code presence no longer appears falsely unmerged, while C1-A remains blocked on consumer fixtures, owner acceptance, qualified review and Founder phase-exit approval.

### D-08 — Pull-request summary was stale

The pull-request body cited superseded head/run evidence and an outdated dependency summary.

**Correction:** after the final successful workflow, the PR body is replaced with the exact final head, current run evidence, final test counts, corrected dependency state and the merge-versus-phase-exit boundary.

## 3. Fresh final review

The correction pass was independently re-reviewed against these invariants:

1. one canonical owner for every clinical fact and mutation;
2. no runtime, real data, secret, binary evidence or private runbook in the public C1-A branch;
3. every mandatory cross-file contract remains versioned, owner-controlled and fail-closed;
4. File 24 assurance never replaces native CF-01 enforcement;
5. no appointment, login, badge, UI state, cache, index or event grants clinical authorization;
6. future clinical writes require expected versions and human-visible conflict handling;
7. signed clinical records remain immutable except through explicit addendum, correction or supersession law;
8. merge readiness of documentation is not represented as legal, clinical, security, staging or production acceptance.

No new clinical runtime was introduced by the correction set.

## 4. Merge-readiness boundary

PR #1 may be marked ready for review only after the corrected exact head and its pull-request merge ref both pass the hardened workflow.

A successful merge would mean only:

- the public-safe C1-A governance foundation is accepted into repository `main`;
- its architecture, threat model, ownership boundaries, traceability and blocking registers become the repository baseline;
- subsequent PRs may rebase on that baseline.

A successful merge does **not** mean:

- C1-A phase exit is accepted;
- companion contracts are frozen;
- retention or jurisdiction rules are approved;
- clinical runtime, package, migration, staging or production is authorized;
- real patient data may be processed.

## 5. Residual blockers preserved

The following remain explicit blockers after repository merge-readiness:

- qualified Pakistan and target-jurisdiction legal/professional decisions;
- approved retention formulas, legal/professional holds and patient-rights rules;
- owner-frozen File 00/02/08/09/17/19/20/25/24 contracts with CF-01 consumer tests;
- provider, storage, region, key, recovery, RPO/RTO and restore evidence;
- named operational owners, deputies, coverage and training;
- independent legal, clinical, privacy, security, accessibility and resilience reports with retests;
- Founder approval of the final C1-A evidence package and explicit authorization to enter C1-B.

## 6. Final decision rule

Known repository-correctable defects identified by this final review must be zero before marking PR #1 ready for review. External blockers may remain only when they are explicitly documented, cannot be truthfully completed inside this repository, and continue to block C1-A phase exit and all clinical runtime authorization.
